The abuse and overdose of opioid drugs are growing public health problems worldwide. Although progress has been made toward understanding the mechanisms governing tolerance to opioids, the exact cellular machinery involved remains unclear. However, there is growing evidence to suggest that c-Jun N-terminal kinases (JNKs) play a major role in mu-opioid receptor regulation and morphine tolerance. In this study, we aimed to determine the potential roles of different JNK isoforms in the development of tolerance to the antinociceptive and hypothermic effects of morphine. We used the hot-plate and tail-flick tests for thermal pain to measure tolerance to the antinociceptive effects of once-daily subcutaneous injections with 10 mg/ kg morphine. Body temperature was also measured to determine tolerance to the hypothermic effects of morphine. Tolerance to morphine was assessed in wild-type mice and compared with single knockout mice each lacking the JNK isoforms (JNK1, JNK2, or JNK3). We found that loss of each individual JNK isoform causes impairment in tolerance for the antinociceptive and hypothermic effects of daily morphine. However, disruption of JNK2 seems to have the most profound effect on morphine tolerance. These results indicate a clear role for JNK signaling pathways in morphine tolerance. This complements previous studies suggesting that the JNK2 isoform is required for morphine tolerance, but additionally presents novel data suggesting that additional JNK isoforms also contribute toward this process.
Introduction
Opioid drugs such as morphine, fentanyl, and oxycodone remain a preferred and commonly prescribed class of drug for pain management [1] . Although they show remarkable efficacy for treating acute pain, there are several limitations to their use. Opioid drugs are associated with rapid development of tolerance and also high abuse potential. Despite this, they remain the default approach to the treatment of many chronic pain conditions. As a result, abuse and overdose of opioids are the fastest growing issues for narcotic drugs in the USA. This is punctuated by a tripling in the rate of prescription opioid overdose in just two decades [1] .
The opioid system is comprised of multiple opioid receptors, each with a unique distribution and function. The antinociceptive effects of many opioid drugs are mediated through the mu-opioid receptor (MOR [2] ), making this receptor one of the most extensively studied G-protein-coupled receptors [3] . MOR is expressed in numerous regions of the central nervous system, among these the dorsal horn of the spinal cord, the periaqueductal gray, and the cortex. As a result, it is a crucial receptor in the modulation of pain circuitry at both the supraspinal and the spinal level. Activation of MOR also causes euphoria, which plays a role in the high addictive liability of opiates [4, 5] . Opioid dependence is compounded by the development of tolerance, which can cause an escalation of dose and a progression to dependence [6] . Because of the decreasing efficacy of repeated opioid use and the resulting prevalence and severity of opioid drug dependence, understanding the mechanisms behind tolerance to these drugs is of significant interest.
There are multiple mechanisms that may act to mediate opioid tolerance [5, 6] . One process termed desensitization occurs with the loss of MOR-effector coupling following opioid administration, and appears to be mediated through phosphorylation of the receptor and subsequent recruitment of β-arrestin [7] . Several previous studies have reported the loss of MOR-effector coupling following agonist treatment [6, 8] . This phenomenon appears to result from phosphorylation of MORs at C-terminal threonine 370 and/or serine 375 [9] . These phosphorylation events are believed to be the result of G-protein-coupled receptor kinase (GRK)2 and/or GRK3 activity, and cause β-arrestin 2 recruitment [7] . β-arrestin 2 causes both the uncoupling of MOR from its associated G proteins and can result in endocytosis [6, 10] . This sequence of events occurs in an agonist-specific manner, and some studies suggest that internalization of MOR does not occur efficiently in response to morphine [10] . Several studies have shown that GRK is responsible for fentanyl, but not morphine tolerance [11, 12] .
Recent work has shown that tolerance to morphine is attenuated through the use of the JNK inhibitor SP600125 [13] [14] [15] [16] . SP600125 is an anthrapyrazolone capable of inhibiting JNK1, JNK2, and JNK3 with high affinity [17] . It has been shown that systematic administration of SP600125 prevents morphine-stimulated phosphorylation of JNK in the spinal cord, resulting in attenuation of tolerance to the antinociceptive and antiallodynic effects of morphine [14, 15] . However, use of this JNK inhibitor is nonselective for the different JNK isoforms and does not enable determination of which isoforms(s) are responsible for morphine tolerance. It has been suggested by recent studies that JNK2 is required for tolerance to the antinociceptive effects of morphine [18] . However, no studies thus far have compared morphine tolerance in JNK1, JNK2, and JNK3 knockout (KO) mice.
Therefore, this novel work examined tolerance to the antinociceptive effects of morphine in JNK1, JNK2, and JNK3 KO mice. We tested the hypothesis that tolerance to morphine would be disrupted in JNK2 KO mice. Although this was indeed the case, we also found that JNK1 (and to a lesser extent) JNK3 also contribute toward morphine tolerance. This finding represents a novel and significant addition to recent work showing the role of JNK signaling in morphine tolerance and MOR regulation.
Methods

Subjects
Experiments were carried out with wild-type (WT) C57BL6/J mice obtained from Jackson Laboratories (Bar Harbor, Maine, USA), and three strains of JNK mutant mice. Mice lacking either JNK1, JNK2, or JNK3 were generously provided by Dr. Charles Chavkin at the University of Washington School of Medicine. The generation of JNK1 KO [19] , JNK2 KO [20] , and JNK3 KO mice [21] has been described previously.
All mice were kept on a standard 12:12 h light-dark cycle with ad libitum access to standard mouse chow and water. All animal care and procedures conformed to the guidelines of the National Institutes of Health on the Care and Use of Animals, and were approved by the Institutional Animal Care and Use Committee of the Pennsylvania State University College of Medicine.
Drugs
Morphine sulfate was obtained from the National Institute on Drug Abuse Drug Supply (Bethesda, Maryland, USA). Morphine was dissolved in isotonic 0.9% saline and administered subcutaneously in an injection volume of 10 ml/kg body weight.
Tail-flick and hot-plate antinociception
Tail-flick antinociception was assessed using a Columbus Instruments TF-1 analgesia meter (Columbus Instruments, Columbus, Ohio, USA). The apparatus was calibrated to elicit an average tail-flick latency of 3-4 s in WT mice. A cutoff time of 10 s was used to prevent tissue damage. Mice were restrained, allowing their tail to be exposed to the radiant heat source. The latency until reflexive tail withdrawal from the heat source was recorded.
Hot-plate antinociception was measured using a Columbus Instruments hot-plate set to 55°C (Columbus Instruments). A 30 s cut-off was used to avoid paw damage. The latency between an animal being placed on the hotplate and withdrawal from the heated surface (jumping, licking of paws) was recorded. Both the hotplate and tail-flick responses were used to calculate the percentage of the maximal possible effect (%MPE). This value was calculated using the formula: % MPE = [(postdrug latency − predrug latency)/(cut-off time − predrug latency)] × 100. These procedures and calculations have been described previously [13, 22] .
Measurement of body temperature
Body temperature was measured using a mouse rectal thermometer probe (Physitemp, Clifton, New Jersey, USA). Hypothermia was reported as a % change in body temperature between predrug and postdrug measurements, as shown by the following formula:
Procedures Antinociception and hypothermia were measured in groups of mice [WT (n = 17), JNK1 KO (n = 15), JNK2 KO (n = 14), and JNK3 KO (n = 20)] receiving daily subcutaneous injections of morphine (10 mg/kg × 10 days). Each day, mice were tested for body temperature, tail-flick, and hot-plate latency immediately before and 1 h after morphine injection.
Data analysis
Antinociception and hypothermia values were expressed as mean SEM. Values were analyzed using two-way analysis of variance (ANOVA) (genotype × day), followed by Bonferroni post-hoc testing. Differences in baseline tail-flick and hot-plate latencies and basal body temperatures were analyzed by one-way ANOVA. Analyses of the initial responses to the first injection of morphine were also carried out by one-way ANOVA. Analyses were carried out using PRISM6 statistical software (Graphpad, La Jolla, California, USA). P less than 0.05 was considered significant.
Results
Tolerance WT mice rapidly developed tolerance to the antinociceptive effects of daily subcutaneous morphine (10 mg/kg) injections in the tail-flick test (Fig. 1 ).
Tolerance to the antinociceptive effect of 10 mg/kg morphine, in the tail-flick test, developed in a timedependent manner (F 9,637 = 12.77, P < 0.0001) and was also dependent on genotype (F 3,637 = 105.6, P < 0.0001).
There was also a significant day × genotype interaction effect (F 27,637 = 3.26, P < 0.0001). Bonferroni post-hoc tests show that tolerance to morphine, in the tail-flick test, was different between WT mice and JNK1 KO (P < 0.0001), JNK2 KO (P < 0.0001), and JNK3 KO mice (P < 0.0001). However, post-hoc testing also indicated that JNK2 KO mice developed less tolerance than either JNK1 KO (P < 0.0001) or JNK3 KO (P < 0.001) mice.
There was no difference in morphine tolerance between JNK1 KO and JNK3 KO mice. Similar results were observed for tolerance to antinociceptive effects of 10 mg/kg morphine in the hot-plate test (Fig. 2) . All mutant mouse groups showed delayed onset of tolerance to the antinociceptive effects of morphine relative to WT mice. Two-way ANOVA analysis shows the main effects of genotype (F 3,577 = 39.39, P < 0.0001) and time (F 9,577 = 32.2, P < 0.0001). However, no significant day × interaction effect was detected (F 27,577 = 1.28, P = 0.155).
Tolerance to morphine-induced hypothermia
Basal body temperature was also different between WT (38.6 0.1°C), and JNK1 KO (37.7 0.1°C; P < 0.001), JNK2 KO (36.8 0.1°C; P < 0.0001), and JNK3 KO (37.1 0.1°C; P < 0.0001) mice. There were differences in basal body temperature between JNK1 and JNK2 KO mice (P < 0.01) as well as JNK1 KO and JNK3 KO mice (P < 0.05). There were also genotype differences in the hypothermic response to morphine (F 3,68 = 6.537, P = 0.0006), with Bonferroni posttests showing that the main effect of genotype was because of differences between WT (− 4.2 0.7% change) and JNK3 KO (− 1.6 0.5% change) mice (P < 0.01) and also between JNK1 (− 4.6 0.4% change) and JNK3 KO mice (P < 0.01). There were no differences between JNK2 KO mice (− 2.5 0.7% change) and the other genotypes.
Rapid tolerance developed to the hypothermic effects of once-daily 10 mg/kg morphine in WT mice (Fig. 3) . Tolerance to the hypothermic effect of 10 mg/kg morphine developed in a time-dependent manner (F 9,607 = 18.44, P < 0.0001) and also depended on the genotype (F 3,607 = 31.24, P < 0.0001). There was also a significant day × genotype interaction effect (F 27,607 = 3.33, P < 0.0001). Bonferroni post-hoc tests show that tolerance to morphine was different between WT mice and JNK1 KO (P < 0.001), JNK2 KO (P < 0.0001), and JNK3 KO mice (P < 0.05). However, post-hoc testing also indicated that JNK2 KO mice also developed less tolerance to morphine hypothermia than JNK3 KO (P < 0.05) mice. There was also a difference in tolerance to the hypothermic effects of morphine between JNK1 KO and JNK3 KO mice (P < 0.0001). However, there was no difference in morphine tolerance between JNK1 KO and JNK2 KO mice.
Discussion
The primary finding of this study is that all three isoforms of JNK (JNK1, JNK2, and JNK3) are involved in tolerance to the antinociceptive and hypothermic effects of morphine. Although deletion of JNK2 had the greatest impact on morphine tolerance, the loss of JNK1 or JNK3 in KO mice also attenuated morphine tolerance. Our results suggest that JNK3 plays the least prominent role in morphine tolerance. These findings are novel in showing that all three forms of JNK contribute toward morphine tolerance, and they are consistent with previous work showing that JNK2 can mediate tolerance to morphine [11, 18] .
Interestingly, disruption of JNK2 appears to have a greater impact on tolerance than the other isoforms in the tail-flick but not the hot-plate test. This may be because of the mediation of tail-flick response primarily by spinal circuitry versus the mediation of hot-plate response by both spinal and supraspinal circuitry [23] . It should also be noted that hot-plate responses are not reflexive, and thus, there is the possibility that they might have been altered by a learning effect because of repeated testing. Although the JNK3 KO mice showed a significant decrease in hypothermic tolerance relative to WT mice, it is important to note that JNK3 KO mice showed a profound difference in the hypothermic response to the first morphine injection. Further investigation is warranted to determine the cause for reduced morphine-induced hypothermia in JNK3 KO mice.
Morphine appears to be different from many other opioids as it does not produce MOR desensitization through the common GRK/β-arrestin pathway [11, 12] . As such, the question of how JNK is mechanistically involved in morphine tolerance is of significant interest.
Morphine results in an increase in spinal JNK phosphorylation through a protein kinase C-dependent process [11] . Furthermore, this effect was abolished in JNK2 KO, but not JNK1 KO or JNK3 KO mice [18] . Both of these studies also indicated that JNK2 KO mice show a reduction in acute morphine tolerance. Despite these results, it should not be concluded that morphine tolerance is strictly the result of JNK2 phosphorylation by protein kinase C. Although other opioids such as fentanyl also cause JNK2 phosphorylation, tolerance to fentanyl is JNK independent [13, 18] . Moreover, although spinal MOR desensitization by morphine requires JNK2, the desensitization of MOR in the locus coeruleus appears to be JNK independent [24] .
Our finding that all three JNK isoforms impact morphine tolerance suggests that morphine tolerance is not always mediated by JNK2 alone. This raises the question of how the other two JNK isoforms might be involved. Although all three JNK isoforms are expressed in parts of the CNS, they have distinct localization patterns and levels of expression in vivo [25] . It is an intriguing possibility that tolerance to specific effects of morphine might be mediated to varying extents by different JNK isoforms. However, it should also be noted that KO of individual JNK isoforms may result in compensatory upregulation of the remaining isoforms. Moving forward, experiments comparing JNK expression and phosphorylation in WT and KO mice would help shed light on potential Tolerance to morphine-induced hypothermia is altered in mutant mice lacking JNK1, JNK2, or JNK3. Wild-type (WT; squares and line), JNK1 KO (circles and dotted line), JNK2 KO (triangles and dashed line), and JNK3 KO (diamonds and dotted line) mice were injected (subcutaneously) with 10 mg/kg morphine once daily for 10 days. All three knockout mouse lines showed impaired tolerance to the hypothermic effect of morphine relative to wild-type animals (P < 0.0001). Data are expressed as mean SEM (n = 15-20 per group).
compensatory effects. Additional investigation is needed to fully understand how JNK signaling pathways contribute toward morphine tolerance and MOR desensitization.
Conclusion
Our findings suggest a possible role for multiple isoforms of JNK in the development of tolerance to morphine. We found a decrease in tolerance to the antinociceptive and hypothermic effects of morphine not only in JNK2 KO mice but also JNK1 KO and JNK3 KO mice. This is a significant step forward in understanding the mechanisms responsible for morphine tolerance. Determining the nature through which these signaling pathways act on MOR will be an important task if JNK pathways are to become a therapeutic target in pain management and opioid abuse.
